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Abstract: Various emerging technologies challenge existing governance processes to identify, 
assess, and manage risk. Though the existing risk-based paradigm has been essential for 
assessment of many chemical, biological, radiological, and nuclear technologies, a 
complementary approach may be warranted for the early-stage assessment and management 
challenges of high uncertainty technologies ranging from nanotechnology to synthetic biology to 
artificial intelligence, among many others. This paper argues for a risk governance approach that 
integrates quantitative experimental information alongside qualitative expert insight to 
characterize and balance the risks, benefits, costs, and societal implications of emerging 
technologies. Various articles in scholarly literature have highlighted differing points of how to 
address technological uncertainty, and this article builds upon such knowledge to explain how an 
emerging technology risk governance process should be driven by a multi-stakeholder effort, 
incorporate various disparate sources of information, review various endpoints and outcomes, 
and comparatively assess emerging technology performance against existing conventional 
products in a given application area. At least in the early stages of development when 
quantitative data for risk assessment remains incomplete or limited, such an approach can be 
valuable for policymakers and decision makers to evaluate the impact that such technologies 
may have upon human and environmental health. 
 
 
 
 
 
Introduction:  
Emerging technologies, including the key enabling technologies, promise revolutionary 
benefits for humanity and the natural environment. However, some of them present uncertain 
risks along with uncertain or untested mechanisms for observation and monitoring. For example, 
the consequences of deploying certain applications deriving from nanotechnology or synthetic 
biology are yet very uncertain (especially if considering issues of biosafety and biosecurity) 
(Konig et al 2016; Mukunda et al 2009). Furthermore, as scientists and industry may not agree in 
either methods for assessing potential risks and consequences and data, various interpretations of 
the science may emerge, together with ambiguity and possible divergent perceptions of risks and 
benefits associated with the technologies (Renn et al 2011; Falkner & Jaspers 2012). Next to 
technologies that have the capacity to fundamentally alter or even synthesize living organisms in 
complex socio-ecological systems and involve challenging issues of values and ethics, some 
emerging technologies may enhance applications of existing technologies involving new 
materials and processes (e.g., graphene or hydraulic fracturing) (Small et al 2014; Linkov et al 
2014).  
The pace of technology development is increasing, and will need regulators and other key 
stakeholders in industry and academia to continue to increase to meet increasing challenges to 
the status quo and to sustainability (Linkov et al 2018). In part, this has led to public suspicion, 
sometimes mistrust, often unease, increasing vulnerability of objective valuations to misclaims 
made by misguided individuals and interest groups, tainting the well of public and consumer 
interest. As our world continues to develop technologically, so too must our ability to deal with a 
heterogeneity of knowledge and level of uncertainties (Scott-Fordsmand et al 2014; Subramanian 
et al 2014; Kuzma et al 2008; Calvert & Martin 2009). Experts, policymakers, and regulators 
should design prospective, adaptive, and knowledge-based benefits and risks assessments and 
governance processes (Tait 2012).   
 Current practice relies upon risk assessment to quantify the risks of materials and 
technologies and upon management to control risks, typically by limiting exposure of humans 
and environmental receptors, are limited to acceptable levels. For mature and well-defined 
technologies, the current risk assessment/management approach has a long history of delivering 
valuable insight to regulators regarding how to establish best practices of policy and governance 
for various fields (Malloy et al 2016; Seager et al 2017; Shatkin 2008).  
However, three features of the conventional approach hinder its effective application to 
emerging technologies. First, it typically requires substantial quantitative data regarding hazards, 
consequences, and exposure regarding the material or technology in question (Rycroft et al 2018; 
Shatkin et al 2016).  Such data is typically unavailable due to the unique qualities of new 
materials as for example, understanding of the impact on human health is an active area of 
research (Epstein & Vermeire 2016). Second, it assumes that the potential consequences of using 
novel materials and technologies can be comprehensively cataloged (Hristozov et al 2012; 
Hristozov et al 2016). Emerging technologies such as synthetic biology and artificial intelligence 
intersect with complex biological, ecological and sociotechnical systems, raising the specter of 
cascading effects and unpredictable outcomes. Given the limitations of current approaches to 
facilitate risk assessment of highly uncertain emerging technologies, a different approach is 
strongly desirable to balance development of innovative technologies with responsible use (see 
additional discussion for biotechnology in Vallero 2015). Finally, an innovation often challenges 
several policy areas that are used to operating in silos, whereas innovation may require more 
flexible, adaptive, and integrated approaches. 
 
Risk Governance for Emerging Technologies 
In this context, it is worth considering the recommendations from the International Risk 
Governance Council, which describe that risk governance sits as the confluence of all analyses 
and actions relative to the development of a given technology (Renn 2005). This includes (i) 
framing the technology in the context of its possible deployment and applications, benefits and 
risks for various stakeholders, (ii) assessing those benefits and risks (including assessment of 
perception and concerns), (iii) evaluating other aspects that decision makers will consider before 
making decisions, such as the existence of specific economic, political or societal interests, or 
also certain issues of national security or ideology, that they want to consider, (iv) identifying 
various risk management options, which they can combine to establish their strategy for the 
development (or not) of the technology, and (v) communicating about risk and benefits. As will 
be described below, the advantages of such a risk governance approach for emerging 
technologies are driven by several key factors, including: the collaborative nature of such an 
approach amongst multiple pertinent stakeholders, its ability to integrate various sources of 
qualitative, semi-quantitative, and quantitative information to assess such technologies, and the 
various criteria of risk, cost, benefit, social implications, and other considerations that are 
inherently valuable to any such governance decision. 
A comprehensive approach to potential risks involved in the development of emerging 
technologies requires a collaborative effort among different stakeholders, as the problem-solving 
capacities of the individual actors within government, industry, academia, and civil society are 
limited and often unequal to the major challenges of governing uncertain risks (Kuzma 2015). 
Therefore, there is a need to engage these stakeholder groups in a continuous dialogue and 
coordinate a profusion of roles, perspectives and goals in the process of the development and 
implementation of safe guidelines and good practices consistent with recent scientific 
advancements (Schmidt et al 2009). Such guidance may arise in the form of formal legal 
requirements, such as new laws or regulatory instruments, or less formally via voluntary 
participation within multi-party codes of conduct.  
A comparative approach in risk governance is needed to address emerging technologies 
of this sort and to prove an environment that fosters responsible innovation (Renn et al 2011; 
Linkov et al 2013). This evolution in risk governance must overcome both institutional 
momentum and vested interests dedicated to the continuance of traditional approaches, a step 
outside our comfort zones effecting change in how we think about risk and its governance. 
Comparative risk governance differs from the conventional approach in several ways.  First, it 
eschews a narrow focus on identifying and controlling quantifiable effects of new materials or 
technologies taken by conventional risk assessment and management (Canis et al 2010). The 
approach should explicitly identify and address the trade-offs that must be made, by assessing 
the risks involved in a proposed new activity against other feasible alternatives, including safer 
designs that avoid or minimize risk by reducing the inherent hazard or exposure of the emerging 
material or technology itself. This idea is visually represented in Figure 1, where disparate 
criteria such as cost, benefit, risk, and social utility are analyzed via relevant utility functions and 
then aggregated via a semi-quantitative metric. This is what the US chemical regulation aims to 
do when it pursues three policy objectives for assessing and regulating (i) the chemical effects on 
human health and the environment, (ii) the benefits of use and the availability of substitutes, and 
(iii) the effects on the economy and innovation.  
Second, recognizing that comprehensive quantitative data will be either unavailable or 
involve too much uncertainty to be reliable, governance should not require the collection of 
absolute measures of acceptable risk.  Instead, governance should be based on collaboration 
between policymakers, regulators, industrial developers, experts, and representatives of society 
from multiple disciplines, in a manner that establishes safe guidelines and best practices 
consistent with recent scientific advancements and expected new developments (Renn 2005; 
Trump et al 2017; Kuiken et al 2014).  
 
Fig. 1. Differentiation of a traditional ‘risk-based’ and a ‘comparative-based’ approach to risk 
policy and governance for emerging technologies 
 
Current practices for emerging technologies must emphasize proactive and adaptive 
approaches to risk management and governance whenever risk assessment is hindered by limited 
availability of experimental data and the state of development (Oye 2012; Tait 2009; Trump 
2017; Cummings et al 2017). Comparative approaches driven by expert opinion and stakeholder 
engagement may help overcome at an early stage the limitations of quantitative risk assessment 
approaches through: 
(i) an impacts analysis of technological substitution based on: 
a. a critical review of the risks potentially associated with an application of an 
emerging technology against a conventional technological application that it 
would replace,  
b. a review of how such a novel technology produces further economic, health, 
or social benefits and costs in lieu of the conventional alternative (Mohan et 
al 2012),  
c. a review of the trade-offs between risks and between risks and opportunities, 
and an explicit and transparent communication about those trade-offs 
(Blaunstein et al 2014; Yatsalo et al 2016),  
d. considerations of other risk factors including social perception and the 
engagement of the public in an evaluation and decision-making process 
(Palma-Oliveira et al 2017; Siegrist et al 2007; Trump et al 2015), as well as 
cost of development that may help or hinder continued research and 
maturation of the emerging technology, and  
(ii) a participative and deliberate decision process to monitor risks and impacts of the 
new technology and integrate feedback into review of initial assessment (and 
subsequent management decisions) (Cummings & Kuzma 2017). 
This is a realistic approach to reviewing the risks and benefits associated with an 
emerging and potentially disruptive technology in a manner that accounts for both physical (e.g. 
health & environment), economic, and social outcomes. The approach requires the willingness of 
the public and private actors and their engagement on knowledge-based adaptive assessment and 
decision processes where new expert judgment and stakeholder opinions data are analyzed and 
integrated as it arises (Linkov et al 2011). If necessary, best practices for technology governance 
would shift, based upon experimentation and testing and integrating feedback into revisions of 
the early decisions. Combining risk characterization with quantitative risk assessments require 
new techniques such as integrating narratives in scenario construction, using stakeholder 
engagement methods for calibrating expert judgments and applying recursive methods of data 
generation and analysis such as cross-balance impact analysis (Mandel & Marchant 2014).  
Expert elicitation has been a valuable tool for potential environmental risks associated 
with nanotechnologies (Trump et al 2018). The U.S. EPA white paper provides a framework for 
integrating empirical information with scientific judgment (Small et al 2014). Indeed, the U.S. 
has followed this framework for numerous comparative risk applications, including regulation of 
particulate matter, nuclear waste and food safety. Uncertainty is particularly large when 
assessing the life cycles of the vast majority of chemical compounds (Csiszar et al 2016; Malloy 
et al 2016; Seager & Linkov 2008)). Since risk is a function of both hazard and exposure, much 
of the uncertainty associated with new chemicals entering the marketplace is due to the paucity 
of reliable information regarding the toxicity, and even greater uncertainty about the frequency 
and extent of an individual’s contact with a specific compound given typical utilizations of that 
chemical (e.g., cosmetics, cleaning products, etc.) and individuals’ use patterns compared to the 
intended use (Grieger et al 2009; Wilson & Schwarzman 2016; Ferson & Sentz 2016; Linkov et 
al 2017). 
 
Discussion 
 Such efforts to develop new approaches for governing risks involved in emerging 
technologies must adopt a holistic perspective of the elements of technology governance. 
Alongside analytical components of risk assessment, other elements should include active 
horizon scanning and anticipatory review of emerging technologies, methodological aspects of 
safe-by-design approaches, effective risk communication and engagement with publics on key 
issues regarding traditional technology risk (e.g. health implications), as well as non-traditional 
risk considerations (e.g. ethical/moral considerations, cost, social impact) (Gronvall 2018). This 
process should also work within the given framework of the jurisdiction at hand, where risk 
governance in the United States, European Union, and elsewhere must account for the unique 
institutional, political, and research environments that influence regulatory decision making and 
policymaking.  
 Ultimately, a risk governance approach for emerging technologies will assist with the 
risk-based approaches utilized by regulators and other risk assessors by accounting for a broad 
view of comparative assessment of emerging and conventional technologies (Tervonen et al 
2009). The approach will help with early-stage guidance for emerging technologies like synthetic 
biology by generating information about expert perceptions of technological risk, benefit, time to 
development, ethics, cost, and various other considerations that all influence how a technology 
may assist with economic, medical, environmental, and social wellbeing (Bates et al 2015). Such 
an approach inherently requires a collaborative effort between various stakeholders for an 
emerging technology’s governance, where input from industry, academia, government, non-
governmental institutions, and civil society at large will not only help evaluate the benefits and 
risks of an uncertain technology, but also address public wariness to adopt and utilize such 
technologies as they enter the marketplace. 
This approach may open new opportunities to improve public trust on regulation as 
informed guidance. A significant dividend of the approach is to facilitate an anticipatory and 
adaptive style of governance for emerging technologies, where governments would be 
increasingly able to perceive the impacts and applications of enabling and emerging technologies 
on the horizon, while iteratively improving risk assessment for such technologies as quantitative 
guidance becomes available (Mandel & Marchant 2014; Trump et al 2017). This approach is 
expected to offer a broader set of evidence-based considerations than traditional risk 
assessment/management, supporting democratic decision making on governing the emerging 
technologies. 
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